Point-of-care Tests for Vaginal Discharge in Nepal
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Jul 26, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, taking place in Nepal, is looking at how new testing methods can help women with vaginal discharge. The main goal is to see if using quick tests for sexually transmitted infections (STIs) can reduce the unnecessary use of antibiotics, which are often prescribed even when not needed. The study will involve 1,500 women who visit a hospital or outreach centers in a semi-rural area of Nepal. Participants will be divided into three groups: one will receive the standard treatment, another will get treatment based on the test results, and the third will receive the test-based treatment along with education about their condition and support for any emotional challenges they may face.
To be eligible for this trial, women must be 18 years or older and experiencing vaginal discharge when they visit the gynecologist. However, those with bleeding, suspected gynecological cancer, or who were part of the study before cannot participate. Throughout the study, participants can expect to receive care based on the approach assigned to their group, and the researchers will also gather feedback on how well these tests are accepted by both patients and healthcare providers. This trial aims to improve the treatment of vaginal discharge and ensure that women receive the right care without unnecessary medications.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women presenting with vaginal discharge to gynecological outpatients
- Exclusion Criteria:
- • Minors below the age of 18 years.
- • Any bleeding from the vagina.
- • Suspicion of gynecological cancer.
- • Previous inclusion in the same study.
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dhulikhel, Kavre, Nepal
Patients applied
Trial Officials
Risa AM Lonnee-Hoffmann, PhD
Principal Investigator
Norwegian University for Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported